Roche, Trimeris withdraw application for Fuzeon injection device

10/3/2007 | News & Observer (Raleigh, N.C.), The · Forbes

Roche Holding subsidiary Hoffmann-La Roche and Trimeris said they are withdrawing their FDA application to market the Biojector 2000 needle-free injection device in combination with HIV drug Fuzeon, following a comprehensive evaluation of a clinical trial and a delay in getting regulatory approval. The companies believe the device isn't an ideal substitute for the delivery of the drug among "all treatment-experienced patients" despite its potential benefits, a Roche official said.

View Full Article in:

News & Observer (Raleigh, N.C.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA